869 related articles for article (PubMed ID: 11329231)
21. Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin.
Blonde L; Sandberg MI; Guthrie RD
Diabetes Care; 1999 Jun; 22(6):1004-6. PubMed ID: 10372262
[No Abstract] [Full Text] [Related]
22. Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution.
Gómez-Pérez FJ; Aguilar-Salinas CA; Vázquez-Chávez C; Fanghänel-Salmón G; Gallegos-Martínez J; Gómez-Diaz RA; Salinas-Orozco S; Chavira-López IJ; Sánchez-Reyes L; Torres-Acosta EM; Tamez R; López A; Guillén LE; Cesarman G
Metabolism; 2002 Jan; 51(1):44-51. PubMed ID: 11782871
[TBL] [Abstract][Full Text] [Related]
23. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.
Ghazzi MN; Perez JE; Antonucci TK; Driscoll JH; Huang SM; Faja BW; Whitcomb RW
Diabetes; 1997 Mar; 46(3):433-9. PubMed ID: 9032099
[TBL] [Abstract][Full Text] [Related]
24. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
Kumar S; Prange A; Schulze J; Lettis S; Barnett AH
Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
[TBL] [Abstract][Full Text] [Related]
25. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI
Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525
[TBL] [Abstract][Full Text] [Related]
26. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.
Imano E; Kanda T; Nakatani Y; Nishida T; Arai K; Motomura M; Kajimoto Y; Yamasaki Y; Hori M
Diabetes Care; 1998 Dec; 21(12):2135-9. PubMed ID: 9839106
[TBL] [Abstract][Full Text] [Related]
27. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
[TBL] [Abstract][Full Text] [Related]
28. Effects of troglitazone in patients with type 2 diabetes mellitus not adequately controlled by sulfonylureas.
Bunnag P; Puavilai G; Chanprasertyotin S; Chandraprasert S; Suwanwalaikorn S; Suthijumroon A; Benjasuratwong Y; Boonyavarakul A; Nitiyanant W; Sriussadaporn S; Deerochanawong C;
Diabetes Res Clin Pract; 2001 Feb; 51(2):151-3. PubMed ID: 11253769
[No Abstract] [Full Text] [Related]
29. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.
Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
Diabetes Care; 1996 Feb; 19(2):151-6. PubMed ID: 8718436
[TBL] [Abstract][Full Text] [Related]
30. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.
Raskin P; Jovanovic L; Berger S; Schwartz S; Woo V; Ratner R
Diabetes Care; 2000 Jul; 23(7):979-83. PubMed ID: 10895850
[TBL] [Abstract][Full Text] [Related]
31. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
[TBL] [Abstract][Full Text] [Related]
32. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
Inzucchi SE; Maggs DG; Spollett GR; Page SL; Rife FS; Walton V; Shulman GI
N Engl J Med; 1998 Mar; 338(13):867-72. PubMed ID: 9516221
[TBL] [Abstract][Full Text] [Related]
34. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group.
Diabetes Care; 1998 Jan; 21(1):87-92. PubMed ID: 9538975
[TBL] [Abstract][Full Text] [Related]
35. Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.
Lewin A; Lipetz R; Wu J; Schwartz S
Clin Ther; 2007 May; 29(5):844-855. PubMed ID: 17697903
[TBL] [Abstract][Full Text] [Related]
36. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
37. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
[TBL] [Abstract][Full Text] [Related]
38. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.
Pavo I; Jermendy G; Varkonyi TT; Kerenyi Z; Gyimesi A; Shoustov S; Shestakova M; Herz M; Johns D; Schluchter BJ; Festa A; Tan MH
J Clin Endocrinol Metab; 2003 Apr; 88(4):1637-45. PubMed ID: 12679450
[TBL] [Abstract][Full Text] [Related]
39. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
[TBL] [Abstract][Full Text] [Related]
40. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes.
Caro JJ; Klittich WS; Raggio G; Kavanagh PL; O'Brien JA; Shomphe LA; Flegel KM; Copley-Merriman C; Sigler C
Clin Ther; 2000 Jan; 22(1):116-27. PubMed ID: 10688395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
